NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PLUR
Pluri Inc.
There isn't enough reported data to score PLUR yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PLUR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
PLUR's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | โ |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
PLUR PE Valuation
PLUR has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PLUR Forward outlook
There aren't enough analyst estimates for PLUR to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PLUR on earnings quality, reporting a profit while its opponent remains loss making.
PLUR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.64 | +$0.49 |
| Q2 2026 | -$2.44 | +$1.12 |
| Q1 2026 | -$2.92 | +$0.69 |
| Q4 2025 | -$3.31 | +$0.37 |
| Q3 2025 | -$3.13 | +$0.98 |
| Q2 2025 | -$3.56 | +$0.43 |
| Q1 2025 | -$3.61 | +$0.60 |
| Q4 2024 | -$3.68 | +$1.04 |
PLUR is still losing money, but far less than before: $2.64 per share over the past year, against $18.08 at its worst in late 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PLUR on profitability, with a higher operating margin.
PLUR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $759K | +140% |
| Q2 2026 | $335K | -16% |
| Q1 2026 | $167K | -61% |
| Q4 2025 | $198K | +7% |
| Q3 2025 | $316K | -3.1% |
| Q2 2025 | $398K | +315% |
| Q1 2025 | $427K | +501% |
| Q4 2024 | $185K | +76% |
PLUR's revenue is growing: $759,000 last quarter, up 140% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2051% | -42 points |
| Q2 2026 | -1656% | +8 points |
| Q1 2026 | -3914% | -2649 points |
| Q4 2025 | -3286% | -606 points |
| Q3 2025 | -2009% | -415 points |
| Q2 2025 | -1664% | +4622 points |
| Q1 2025 | -1265% | +6530 points |
| Q4 2024 | -2679% | +2285 points |
PLUR's operating margin was โ2051% last quarter, down 42 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over PLUR on cash generation, producing positive trailing cash flow while its opponent burns cash.
PLUR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.5M | +$995K |
| Q2 2026 | -$4.5M | +$1.5M |
| Q1 2026 | -$4.6M | +$324K |
| Q4 2025 | -$5.7M | -$912K |
| Q3 2025 | -$5.5M | -$1.3M |
| Q2 2025 | -$5.9M | -$1.6M |
| Q1 2025 | -$4.9M | -$589K |
| Q4 2024 | -$4.7M | -$970K |
PLUR has burned cash in almost every quarter: โ$19M over the past year, against โ$21M the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PLUR Net Leverage
PLUR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PLUR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 33.6 | Neutral |
PLUR's weekly RSI is 33 (neutral) and its Stochastic is 34 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PLUR PE vs Healthcare Sector
PLUR has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PLUR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.06 | 2.8% above |
| 20 week MA | $1.39 | 22% below |
| 50 week MA | $2.42 | 55% below |
| 100 week MA | $3.51 | 69% below |
| 200 week MA | $4.74 | 77% below |
PLUR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 77% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over PLUR on returns for 2026, with the stronger performance.
PLUR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.5 | $57.7 | +78% |
| 2021 | $57.7 | $15.5 | -73% |
| 2022 | $15.5 | $8.00 | -48% |
| 2023 | $8.00 | $4.64 | -42% |
| 2024 | $4.64 | $4.55 | -1.9% |
| 2025 | $4.55 | $3.11 | -32% |
| 2026 YTD | $3.11 | $1.09 | -65% |
PLUR has finished five years in a row lower, and it's down 65% so far in 2026.